Draw-To-Thaw Platform
Explore a simplified solution for cell and gene therapy development and manufacturing that begins and ends with the patient.
A business unit of the New York Blood Center Enterprises, Comprehensive Cell Solutions (CCS) is a cell and gene therapy-focused development and manufacturing organization that provides critical capacity to an underserved population of early-stage developers, as well as expertise and strategic footprint for hospital treatment centers and pharmaceutical organizations.
With a 50-year history of excellence in blood operations, collection facilities in 17 states, and partnerships with major hospitals, CCS offers a true end-to-end solution for our cell therapy clients. We call this our “draw to thaw” platform, a unique offering that begins and ends with the patient, accelerating the time from apheresis to treatment.
Learn how this streamlined solution — in partnership with GenScript ProBio to support production of Lentivirus, Retrovirus, Plasmid, RNA, and LNPs — is reducing time to patient treatment and expanding access to life-saving treatments.